Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting

BACKGROUND: Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced musculoskeletal symptoms are common and may be accused for treatment discontinuation. Recentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Skafida, Efthymia, Andrikopoulou, Angeliki, Terpos, Evangelos, Markellos, Christos, Moustafa, Savvina, Pectasides, Dimitrios, Dimopoulos, Meletios-Athanasios, Zagouri, Flora, Vassilopoulos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247331/
https://www.ncbi.nlm.nih.gov/pubmed/37293258
http://dx.doi.org/10.1155/2023/3614296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247331/
https://www.ncbi.nlm.nih.gov/pubmed/37293258
http://dx.doi.org/10.1155/2023/3614296

Ejemplares similares